Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model

mAbs

Volumn 5, Issue 2, 2013, Pages 263-269

  Zeitlin, Larry ^a   Bohorov, Ognian ^a   Bohorova, Natasha ^a   Hiatt, Andrew ^a   Kim, Do H ^a   Pauly, Michael H ^a   Velasco, Jesus ^a   Whaley, Kevin J ^a   Barnard, Dale L ^b   Bates, John T ^c   Crowe, James E ^c   Piedra, Pedro A ^d   Gilbert, Brian E ^d  

^a Mapp Biopharmaceutical Inc ^*  (United States)

^b UTAH STATE UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Antibody; Monoclonal; Nicotiana; Prophylaxis; RSV; Therapy

Indexed keywords

EPITOPE; PALIVIZUMAB;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; COTTON RAT; IMMUNOPROPHYLAXIS; IN VIVO STUDY; MOUSE; MYELOMA CELL; NICOTIANA; NONHUMAN; NUCLEOTIDE SEQUENCE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS;

EID: 84876531530     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.23281     Document Type: Article

References (37)

1. Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999; 354: 541-5; PMID:10470697; http://dx.doi.org/10.1016/ S0140-6736(98)10321-5
2. Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr 2003; 143(Suppl):S127-32; PMID:14615711; http://dx.doi.org/10.1067/S0022- 3476(03)00510-9
3. Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. Clin Microbiol Rev 2000; 13: 371-84; PMID:10885982; http://dx.doi.org/10.1128/ CMR.13.3.371-384.2000
4. Bowden RA. Respiratory virus infections after marrow transplant: the Fred Hutchinson Cancer Research Center experience. Am J Med 1997; 102(3A): 27-30, discussion 42-3; PMID:10868139; http://dx.doi.org/10.1016/S0002-9343(97)00007-7
5. Storey S. Respiratory syncytial virus market. Nat Rev Drug Discov 2010; 9: 15-6; PMID:20043025; http://dx.doi.org/10.1038/nrd3075
6. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102: 531-7; http://dx.doi.org/10.1542/peds.102.3.531
7. Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 1999; 104: 419-27; PMID:10469764; http://dx.doi.org/10.1542/ peds.104.3.419
8. Lofland JH, O'Connor JP, Chatterton ML, Moxey ED, Paddock LE, Nash DB, et al. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis. Clin Ther 2000; 22: 1357-69; PMID:11117660; http://dx.doi.org/10.1016/ S0149-2918(00)83032-5
9. Numa A. Outcome of respiratory syncytial virus infection and a cost-benefit analysis of prophylaxis. J Paediatr Child Health 2000; 36: 422-7; PMID:11036794; http://dx.doi.org/10.1046/j.1440-1754.2000.00303.x
10. Barton LL, Grant KL, Lemen RJ. Respiratory syncytial virus immune globulin: decisions and costs. Pediatr Pulmonol 2001; 32: 20-8; PMID:11416872; http://dx.doi.org/10.1002/ppul.1084
11. Vogel AM, McKinlay MJ, Ashton T, Lennon DR, Harding JE, Pinnock R, et al. Cost-effectiveness of palivizumab in New Zealand. J Paediatr Child Health 2002; 38: 352-7; PMID:12173995; http://dx.doi.org/10.1046/j.1440-1754.2002.00790.x
12. Roeckl-Wiedmann I, Liese JG, Grill E, Fischer B, Carr D, Belohradsky BH. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany. Eur J Pediatr 2003; 162: 237-44; PMID:12647196
13. Rietveld E, Steyerberg EW, Polder JJ, Veeze HJ, Vergouwe Y, Huysman MW, et al. Passive immunisation against respiratory syncytial virus: a cost-effectiveness analysis. Arch Dis Child 2010; 95: 493-8; PMID:20504841; http://dx.doi.org/10.1136/ adc.2008.155556
14. Storch GA. Humanized monoclonal antibody for prevention of respiratory syncytial virus infection. Pediatrics 1998; 102: 648-51; PMID:9738192; http://dx.doi.org/10.1542/peds.102.3.648
15. The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997; 99: 93-9; PMID:8989345; http://dx.doi.org/10.1542/peds.99.1.93
16. Wang D, Bayliss S, Meads C. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses. Health Technol Assess 2011; 15:iii-iv, 1-124; PMID:21281564
17. Chamat S, Walsh EE, Anderson D, Osta M, Awaraji C, Pan LZ, et al. Human monoclonal antibodies isolated from spontaneous Epstein-Barr virus-transformed tumors of Hu-SPL-SCID mice and specific for fusion protein display broad neutralizing activity toward respiratory syncytial virus. J Infect Dis 1999; 180: 268-77; PMID:10395839; http://dx.doi.org/10.1086/314876
18. Barbas CF 3rd, Crowe JE Jr., Cababa D, Jones TM, Zebedee SL, Murphy BR, et al. Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity. Proc Natl Acad Sci U S A 1992; 89: 10164-8; PMID:1279672; http://dx.doi.org/10.1073/ pnas.89.21.10164
19. Crowe JE Jr., Gilmour PS, Murphy BR, Chanock RM, Duan L, Pomerantz RJ, et al. Isolation of a second recombinant human respiratory syncytial virus monoclonal antibody fragment (Fab RSVF2- 5) that exhibits therapeutic efficacy in vivo. J Infect Dis 1998; 177: 1073-6; PMID:9534985; http://dx.doi.org/10. 1086/517397
20. Crowe JE Jr., Murphy BR, Chanock RM, Williamson RA, Barbas CF 3rd, Burton DR. Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice. Proc Natl Acad Sci U S A 1994; 91: 1386-90; PMID:8108420; http://dx.doi.org/10.1073/pnas.91.4.1386
21. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997; 176: 1215-24; PMID:9359721; http://dx.doi.org/10.1086/514115
22. Hiatt A, Cafferkey R, Bowdish K. Production of antibodies in transgenic plants. Nature 1989; 342: 76-8; PMID:2509938; http://dx.doi.org/10.1038/342076a0
23. Marillonnet S, Thoeringer C, Kandzia R, Klimyuk V, Gleba Y. Systemic Agrobacterium tumefaciens-mediated transfection of viral replicons for efficient transient expression in plants. Nat Biotechnol 2005; 23: 718-23; PMID:15883585; http://dx.doi.org/10.1038/nbt1094
24. Hiatt A, Pauly M. Monoclonal antibodies from plants: a new speed record. Proc Natl Acad Sci U S A 2006; 103: 14645-6; PMID:17000998; http://dx.doi.org/ 10.1073/pnas.0607089103
25. Strasser R, Stadlmann J, Schähs M, Stiegler G, Quendler H, Mach L, et al. Generation of glycoengineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. Plant Biotechnol J 2008; 6: 392-402; PMID:18346095; http://dx.doi.org/10.1111/j.1467- 7652.2008.00330.x
26. Pogue GP, Vojdani F, Palmer KE, Hiatt E, Hume S, Phelps J, et al. Production of pharmaceutical-grade recombinant aprotinin and a monoclonal antibody product using plant-based transient expression systems. Plant Biotechnol J 2010; 8: 638-54; PMID:20514694; http://dx.doi.org/10.1111/j.1467- 7652.2009.00495.x
27. Piedra PA, Wyde PR, Castleman WL, Ambrose MW, Jewell AM, Speelman DJ, et al. Enhanced pulmonary pathology associated with the use of formalininactivated respiratory syncytial virus vaccine in cotton rats is not a unique viral phenomenon. Vaccine 1993; 11: 1415-23; PMID:7508665; http://dx.doi.org/10.1016/ 0264-410X(93)90170-3
28. Whaley KJ, Hiatt A, Zeitlin L. Emerging antibody products and Nicotiana manufacturing. [Review]. Hum Vaccin 2011; 7: 349-56; PMID:21358287; http://dx.doi.org/10.4161/hv.7.3.14266
29. Yusibov V, Streatfield SJ, Kushnir N. Clinical development of plant-produced recombinant pharmaceuticals: vaccines, antibodies and beyond. [Review]. Hum Vaccin 2011; 7: 313-21; PMID:21346417; http://dx.doi.org/10.4161/ hv.7.3.14207
30. Zeitlin L, Olmsted SS, Moench TR, Co MS, Martinell BJ, Paradkar VM, et al. A humanized monoclonal antibody produced in transgenic plants for immunoprotection of the vagina against genital herpes. Nat Biotechnol 1998; 16: 1361-4; PMID:9853620; http://dx.doi.org/10.1038/4344
31. Ko K, Koprowski H. Plant biopharming of monoclonal antibodies. Virus Res 2005; 111: 93-100; PMID:15896408; http://dx.doi.org/10.1016/j. virusres.2005.03.016
32. Zeitlin L, Pettitt J, Scully C, Bohorova N, Kim D, Pauly M, et al. Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc Natl Acad Sci U S A 2011; 108: 20690-4; PMID:22143789; http://dx.doi.org/10.1073/pnas.1108360108
33. Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 2001; 13: 1551-9; PMID:11717196; http://dx.doi.org/10. 1093/intimm/13.12.1551
34. Shah JN, Chemaly RF. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood 2011; 117: 2755-63; PMID:21139081; http://dx.doi.org/10.1182/blood-2010-08-263400
35. Farid SS. Process economics of industrial monoclonal antibody manufacture. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 848: 8-18; PMID:16899415; http://dx.doi.org/10.1016/j.jchromb.2006.07.037
36. Bendandi M, Marillonnet S, Kandzia R, Thieme F, Nickstadt A, Herz S, et al. Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin's lymphoma. Ann Oncol 2010; 21: 2420-7; PMID:20494963; http://dx.doi.org/10.1093/ annonc/mdq256
37. Heard C, Brams P, Walsh E, Huynh T, Chamat S, Reff M, et al. Two neutralizing human anti-RSV antibodies: cloning, expression, and characterization. Mol Med 1999; 5: 35-45; PMID:10072446